Experimental allergic neuritis: effect of plasma infusions

Area of Science:

• Immunology
• Neuroscience
• Veterinary Medicine

Background:

• Chronic experimental allergic neuritis (EAN) is an autoimmune model of demyelinating disease.
• Current treatments for EAN have limitations, necessitating exploration of novel therapeutic strategies.
• The role of plasma components and volume expansion in modulating autoimmune responses in EAN is not fully understood.

Purpose of the Study:

• To investigate the therapeutic potential of intravenous fresh frozen plasma (FFP) and artificial plasma expanders in chronic EAN.
• To assess the impact of these infusions on clinical symptoms and anti-myelin immunoglobulin G (IgG) levels in EAN rabbits.
• To determine if observed effects are immunologically mediated or due to plasma dilution.

Main Methods:

• Chronic EAN was induced in rabbits.
• Animals were allocated to receive either rabbit FFP, a gelatin plasma expander (Haemaccel), or no treatment (control).
• Clinical scores, plasma anti-myelin IgG levels (ELISA), and plasma cortisol concentrations were monitored throughout the study.

Main Results:

• FFP infusions (15 ml/kg/day for 8 days) significantly improved clinical symptoms in EAN rabbits compared to controls.
• Artificial plasma expander (Haemaccel) showed no significant clinical benefit.
• FFP treatment led to a significant decrease in anti-myelin IgG levels 24 hours post-infusion, suggesting an immunological effect, while Haemaccel only caused temporary dilution.

Conclusions:

• Intravenous FFP administration during the early stages of chronic EAN can induce clinical remission in affected animals.
• FFP's therapeutic effect appears to be immunologically mediated, likely through the reduction of pathogenic anti-myelin IgG.
• Artificial plasma expanders are not effective in treating chronic EAN, highlighting the specific benefits of FFP.